Nuvilex Completes First Sale of Last Shot Hangover Remedy(TM)
July 15 2009 - 3:48PM
PR Newswire (US)
Inventory Production Ahead of Schedule CHERRY HILL, N.J., July 15
/PRNewswire-FirstCall/ -- Nuvilex, Inc. (OTC Bulletin Board: NVLX),
announced today that it completed its first sale of its Last Shot
Hangover Remedy. The sale, a 36 shot case of Last Shot Hangover
Remedy(TM), was made to a local bar establishment by the first of
Nuvilex' fifteen new commission sales representatives. The sale
marks Nuvilex' official launch of its Last Shot Hangover Remedy(TM)
across the U.S., concentrating in major markets in the following
order: Philadelphia, New York City, Miami, Chicago, Las Vegas, San
Francisco, Los Angeles, San Diego, Boston, Washington, DC, Atlanta,
New Orleans, Dallas, Phoenix, and Seattle. The initial target
customers are the approximate 70,000 bar establishments in the US.
The Company, through third party distributor agreements, will
expand to restaurants, clubs, resort hotels and international
markets later this year. Direct to consumer Internet sales will
commence in August 2009. Last Shot Hangover Remedy(TM) is a
calorie-free, liquid, nutritional supplement that contains a
concentrated blend of vitamins, essential amino acids, and other
beneficial ingredients. Last Shot Hangover Remedy(TM) helps the
body to combat symptoms that are associated with alcohol-induced
hangovers, including nausea, fatigue, and headache. Last Shot
Hangover Remedy(TM) retails for $4.00 per three quarter ounce shot.
Approximately 35 hangover remedy products are currently sold
worldwide, generally through pharmacies. Nuvilex' "at the bar"
distribution strategy is a market differentiator and provides a
competitive advantage that ideally fits with the unanticipated
consequences of excessive alcohol consumption. The total potential
market size in the US for hangover remedy products is estimated to
be $10-50 million per year. The Company forecasts $1 to $3 million
in Last Shot Hangover Remedy(TM) sales for FY 2010 and substantial
growth in subsequent years. In March 2009, Nuvilex conducted a
proof of concept study among 6,000 college-aged students who drank
to the point of intoxication. Nuvilex determined the efficacy of
Last Shot by asking study participants to indicate what symptoms
they experienced during excessive alcohol consumption with and
without Last Shot. The feedback the Company received on the
efficacy of Last Shot was overwhelmingly positive; students who
drank to excess (defined as > 6 drinks/night) and did not
receive Last Shot were nearly 6 times more likely to experience a
hangover or symptoms that are associated with a hangover. Nuvilex
has conceived, formulated, tested, test marketed, commenced pilot
scale manufacturing and launched its Last Shot Hangover Remedy(TM)
in less than six months. The Company, in pilot scale, is capable of
producing 1,000 cases per month. Full-scale production, via an FDA
certified packing company; with full market production capabilities
will be online by September 2009. At full-scale production levels,
the Company believes it can achieve a greater than 75% gross
margin. Nuvilex, as part of its comprehensive marketing plan for
its Last Shot Hangover Remedy, is producing a thirty and
sixty-second Last Shot Hangover Remedy video commercial, which will
be ready to air through various media outlets by August 1, 2009.
The video commercial is being directed by Miller + Partners, Coral
Springs, FL. "Nuvilex is a small company and we are very proud of
our ability to get the Last Shot Hangover Remedy(TM) out of the lab
and into the market in record time," said Martin Schmieg, Chairman
and Chief Executive Officer of Nuvilex, Inc. "The Last Shot
Hangover Remedy(TM) is a fun and highly effective product. Our 'at
the bar' marketing strategy is intended to make the Last Shot
Hangover Remedy 'a part of the party'. Everyone enjoys a good
party. Our Last Shot Hangover Remedy is designed for a better
morning after. We are extremely excited to have introduced the Last
Shot Hangover Remedy into the large and fragmented hangover remedy
market, and we are confident in the revenues and stabilizing
profits Last Shot will bring to the Company." About Nuvilex, Inc.
Nuvilex, Inc. is an emerging healthcare consumer products company.
The Company's lead products include: Last Shot Hangover Remedy, a
unique sugar-free, calorie-free and caffeine-free liquid formula
designed to ease the symptoms of a hangover; Cinnergen, which
promotes a healthy glucose metabolism; Cinnechol, designed to help
maintain normal cholesterol levels and support normal
cardiovascular function; and Infinitink , a permanent yet more
easily removable tattoo ink. The Company's complete portfolio spans
aesthetics, dermatology, environmental and nutraceutical products,
all of which are designed to directly or indirectly improve human
health. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc.,
the developer of Infinitink . In conjunction with the merger, the
Company changed its name to Nuvilex, Inc. from eFoodSafety.com.
Please visit http://www.nuvilex.com/ for additional information on
the Company. Safe Harbor Statement Statements contained in this
presentation that are not strictly historical are "forward-looking"
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities and Exchange Act of 1934.
The forward-looking statements are made based on information
available as of the date hereof, and the Company assumes no
obligation to update such forward-looking statements.
Forward-looking statements are sometimes identified by words such
as "intends", "anticipates", "believes", "expects", and "hopes" and
involve a number of risks and uncertainties that could cause the
Company's actual results to differ materially from projected
results. All parties are cautioned that such forward-looking
statements involve risks and uncertainties that could cause the
Company's actual results to differ materially from those in these
forward-looking statements. Such risks and uncertainties include
but are not limited to demand for the Company's products and
services, the planned share exchange with Freedom2 Holdings, Inc.,
our ability to secure additional financing, and other factors that
may be more fully described in reports to shareholders and periodic
filings with the Securities and Exchange Commission. Blair Barnes
Senior Vice President and Chief Financial Officer Nuvilex, Inc. Ph:
856-433-6088 Email: Amy Glynn/Ashleigh Barreto The Ruth Group Ph:
646-536-7023/7028 Email: Email: Press Contact: Pat Arcand Arcand
& Madison Ph: 617-576-7777 Email: DATASOURCE: Nuvilex, Inc.
CONTACT: Blair Barnes, Senior Vice President and Chief Financial
Officer of Nuvilex, Inc., +1-856-433-6088, ; or Amy Glynn/Ashleigh
Barreto both of The Ruth Group, +1-646-536-7023/7028, , ; or Press
Contact, Pat Arcand of Arcand & Madison, +1-617-576-7777, Web
Site: http://www.nuvilex.com/
Copyright